The case for Supported Treatment is not soft. A 1% improvement in patient persistence is worth approximately ten times more in revenue than a 1% improvement in acquisition. But that argument has to be built with your numbers, in your therapeutic area, for your budget committee. Generic ROI frameworks do not survive internal scrutiny. This work builds the one that does.
→ Model the revenue impact of persistence improvement scenarios specific to your therapeutic area, treatment duration, and current discontinuation rates
→ Quantify the acquisition dilution cost — the revenue lost when early drop-off means new patients replace existing patients rather than growing the treated base
→ Build the investment case for Supported Treatment as a corporate capability, including upfront development cost, operating model, and projected return across the product lifecycle
→ Develop the payer value narrative: how improved adherence and persistence translates into health economic outcomes that support formulary positioning and reimbursement discussions
→ Benchmark commercial outcomes from published PSP evidence — including HUMIRA Complete, iCAN, and cross-therapeutic adherence programme data — and translate findings to your context
→ Map the competitive risk of inaction: what happens to market position and patient lifetime value if generic entry or a competitor’s programme arrives before yours does
→ Build the patent expiry scenario: how a well-governed Supported Treatment programme changes the post-generic retention curve and what evidence is needed to support it
→ Develop the real-world evidence monetisation strategy — how adherence and outcome data from the programme creates commercial value beyond the direct persistence uplift
→ Prepare the executive presentation: how to frame Supported Treatment investment for a Board or C-suite audience that has historically managed patient engagement as a cost, not a commercial asset
→ Define the financial governance model — funded P&L ownership, multi-year commitment structure, and how returns are measured and reported — that protects the investment through brand transitions